Physician profile
Rita Nanda
NPI 1568524015
$286,462.76
in general payments reported to CMS, 2019-2025
23 companies · $38K in 2025
The $38K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $16K · 2021: $18K · 2022: $25K · 2023: $75K · 2024: $56K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $95K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Travel and Lodging: $34K · Food and Beverage: $3,538 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $95,356.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,361.00 |
| Travel and Lodging | $33,696.65 |
| Food and Beverage | $3,538.41 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $842.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $66,794.88 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $59,276.15 | 2019-2024 | |
| Genentech USA, INC. | $47,820.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $23,606.65 | 2022-2025 | Enhertu, Lynparza |
| Pfizer INC. | $21,552.71 | 2019-2025 | |
| Daiichi Sankyo INC. | $19,061.88 | 2023-2025 | Enhertu, Datroway |
| Seagen INC. | $11,034.85 | 2020-2023 | Tukysa |
| Genzyme Corporation | $8,563.26 | 2022 | |
| Ge Healthcare | $6,407.14 | 2022-2024 | |
| Immunomedics, INC. | $5,150.00 | 2020 | |
| Corcept Therapeutics | $4,654.93 | 2025 | |
| Astrazeneca Uk Limited | $3,217.50 | 2022-2025 | Datroway |
| Eli Lilly and Company | $2,829.87 | 2024 | Verzenio |
| Modernatx, INC. | $2,746.25 | 2023 | |
| Clovis Oncology, INC. | $1,612.74 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer International LLC | $1,366.20 | 2019 | |
| Stemline Therapeutics INC. | $767.25 | 2022-2025 | Orserdu |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Nanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.